Study Stopped
The MMRF has learned of the limitations of using a blood sample to collect genomic data, compared to a bone marrow aspirate. We decided that our resources are best served in other areas at this time.
MMRF CureCloud Research Initiative
The MMRF CureCloud Multiple Myeloma Research Initiative
1 other identifier
observational
1,105
1 country
4
Brief Summary
The MMRF CureCloud Research Initiative, a Direct-to-Patient Research effort aimed at enrolling 5,000 individuals from whom comprehensive molecular and immune analyses will be generated from blood specimens and the resulting data aggregated with the correlating clinical information. Blood will be collected from all participants after electronic online consenting via a mailed blood kit designed for a mobile phlebotomy appointment. Through the consenting process, participants will also be authorizing collection of their electronic medical records information.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jul 2020
Typical duration for all trials
4 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 28, 2018
CompletedFirst Posted
Study publicly available on registry
September 5, 2018
CompletedStudy Start
First participant enrolled
July 14, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 29, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2023
CompletedJanuary 5, 2024
January 1, 2024
3.5 years
August 28, 2018
January 2, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
Collection and Analyses of Clinical Information and Peripheral Blood Samples
Patients that have been diagnosed with active Multiple Myeloma will be asked to share their clinical information and blood samples to help scientists and researchers understand these conditions better. The study will use submitted blood samples to perform comprehensive research that will include, among others, genomic and immune characterization, as well as collect past and present medical records to combine and compare with the blood sample analysis.
5 years
Study Arms (1)
CureCloud Direct to Patient
Interventions
Participants will be asked to provide up to a maximum total 40 mL of blood for all of the required sample collection. Peripheral blood will be collected from patients who consent to the protocol. These samples will be obtained at a time scheduled by the participant with the phlebotomy service provider, and will be collected at the participant's home. Patient peripheral blood samples can be obtained at diagnosis or at any time in follow up.
Eligibility Criteria
This protocol is designed to collect peripheral blood samples with annotated clinical data from patients with active Multiple Myeloma
You may qualify if:
- Patients diagnosed with active Multiple Myeloma
- Patients have signed an online consent form
You may not qualify if:
- Patients who live outside the United States
- Patients with a diagnosis other than Multiple Myeloma or a known or suspected precursor to Multiple Myeloma
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (4)
Multiple Myeloma Research Foundation
Norwalk, Connecticut, 06851, United States
Washington University Medical Campus
St Louis, Missouri, 63110, United States
Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
University of Texas Southwestern Medical Center
Dallas, Texas, 75390, United States
Biospecimen
Blood will be collected from all participants after electronic online consenting via a mailed blood kit designed for a mobile phlebotomy appointment.
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Hearn J Cho, MD, PhD
Multiple Myeloma Research Foundation
- PRINCIPAL INVESTIGATOR
George Mulligan, PhD
Multiple Myeloma Research Foundation
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- PROSPECTIVE
- Target Duration
- 5 Years
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 28, 2018
First Posted
September 5, 2018
Study Start
July 14, 2020
Primary Completion
December 29, 2023
Study Completion
December 31, 2023
Last Updated
January 5, 2024
Record last verified: 2024-01